288 related articles for article (PubMed ID: 16033839)
21. Anti-CD22 90Y-epratuzumab tetraxetan combined with anti-CD20 veltuzumab: a phase I study in patients with relapsed/refractory, aggressive non-Hodgkin lymphoma.
Witzig TE; Tomblyn MB; Misleh JG; Kio EA; Sharkey RM; Wegener WA; Goldenberg DM
Haematologica; 2014 Nov; 99(11):1738-45. PubMed ID: 25150258
[TBL] [Abstract][Full Text] [Related]
22. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma.
Knox SJ; Goris ML; Trisler K; Negrin R; Davis T; Liles TM; Grillo-López A; Chinn P; Varns C; Ning SC; Fowler S; Deb N; Becker M; Marquez C; Levy R
Clin Cancer Res; 1996 Mar; 2(3):457-70. PubMed ID: 9816191
[TBL] [Abstract][Full Text] [Related]
23. A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer.
Scott AM; Wiseman G; Welt S; Adjei A; Lee FT; Hopkins W; Divgi CR; Hanson LH; Mitchell P; Gansen DN; Larson SM; Ingle JN; Hoffman EW; Tanswell P; Ritter G; Cohen LS; Bette P; Arvay L; Amelsberg A; Vlock D; Rettig WJ; Old LJ
Clin Cancer Res; 2003 May; 9(5):1639-47. PubMed ID: 12738716
[TBL] [Abstract][Full Text] [Related]
24. Use of ibritumomab tiuxetan anti-CD20 radioimmunotherapy in a non-Hodgkin's lymphoma patient previously treated with a yttrium-90-labeled anti-CD22 monoclonal antibody.
Tsai DE; Maillard I; Schuster SJ; Nasta SD; Porter DL; Klumpp TR; Goldenberg DM; Luger SM; Alavi A; Sharkey RM; Hartzell KB; Stadtmauer EA
Clin Lymphoma; 2003 Jun; 4(1):56-9. PubMed ID: 12837157
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of response to fractionated radioimmunotherapy with 90Y-epratuzumab in non-Hodgkin's lymphoma by 18F-fluorodeoxyglucose positron emission tomography.
Bodet-Milin C; Kraeber-Bodéré F; Dupas B; Morschhauser F; Gastinne T; Le Gouill S; Campion L; Harousseau JL; Wegener WA; Goldenberg DM; Huglo D
Haematologica; 2008 Mar; 93(3):390-7. PubMed ID: 18268287
[TBL] [Abstract][Full Text] [Related]
26. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study.
Advani A; Coiffier B; Czuczman MS; Dreyling M; Foran J; Gine E; Gisselbrecht C; Ketterer N; Nasta S; Rohatiner A; Schmidt-Wolf IG; Schuler M; Sierra J; Smith MR; Verhoef G; Winter JN; Boni J; Vandendries E; Shapiro M; Fayad L
J Clin Oncol; 2010 Apr; 28(12):2085-93. PubMed ID: 20308665
[TBL] [Abstract][Full Text] [Related]
27. 67Copper-2-iminothiolane-6-[p-(bromoacetamido)benzyl-TETA-Lym-1 for radioimmunotherapy of non-Hodgkin's lymphoma.
O'Donnell RT; DeNardo GL; Kukis DL; Lamborn KR; Shen S; Yuan A; Goldstein DS; Mirick GR; DeNardo SJ
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3330s-3336s. PubMed ID: 10541382
[TBL] [Abstract][Full Text] [Related]
28. A phase I trial combining high-dose 90Y-labeled humanized anti-CEA monoclonal antibody with doxorubicin and peripheral blood stem cell rescue in advanced medullary thyroid cancer.
Sharkey RM; Hajjar G; Yeldell D; Brenner A; Burton J; Rubin A; Goldenberg DM
J Nucl Med; 2005 Apr; 46(4):620-33. PubMed ID: 15809485
[TBL] [Abstract][Full Text] [Related]
29. CD22 as a target of passive immunotherapy.
Cesano A; Gayko U
Semin Oncol; 2003 Apr; 30(2):253-7. PubMed ID: 12720147
[TBL] [Abstract][Full Text] [Related]
30. 90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma.
Griffiths GL; Govindan SV; Sharkey RM; Fisher DR; Goldenberg DM
J Nucl Med; 2003 Jan; 44(1):77-84. PubMed ID: 12515879
[TBL] [Abstract][Full Text] [Related]
31. 188Re or 90Y-labelled anti-CD66 antibody as part of a dose-reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55: results of a phase I-II study.
Ringhoffer M; Blumstein N; Neumaier B; Glatting G; von Harsdorf S; Buchmann I; Wiesneth M; Kotzerke J; Zenz T; Buck AK; Schauwecker P; Stilgenbauer S; Döhner H; Reske SN; Bunjes D
Br J Haematol; 2005 Aug; 130(4):604-13. PubMed ID: 16098076
[TBL] [Abstract][Full Text] [Related]
32. (90)Y-labelled anti-CD22 epratuzumab tetraxetan in adults with refractory or relapsed CD22-positive B-cell acute lymphoblastic leukaemia: a phase 1 dose-escalation study.
Chevallier P; Eugene T; Robillard N; Isnard F; Nicolini F; Escoffre-Barbe M; Huguet F; Hunault M; Marcais A; Gaschet J; Cherel M; Guillaume T; Delaunay J; Peterlin P; Eveillard M; Thomas X; Ifrah N; Lapusan S; Bodet-Milin C; Barbet J; Faivre-Chauvet A; Ferrer L; Bene MC; Le Houerou C; Goldenberg DM; Wegener WA; Kraeber-Bodéré F
Lancet Haematol; 2015 Mar; 2(3):e108-17. PubMed ID: 26687796
[TBL] [Abstract][Full Text] [Related]
33. Change in tumor-absorbed dose due to decrease in mass during fractionated radioimmunotherapy in lymphoma patients.
Hindorf C; Lindén O; Stenberg L; Tennvall J; Strand SE
Clin Cancer Res; 2003 Sep; 9(10 Pt 2):4003S-6S. PubMed ID: 14506200
[TBL] [Abstract][Full Text] [Related]
34. Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma.
Advani R; Forero-Torres A; Furman RR; Rosenblatt JD; Younes A; Ren H; Harrop K; Whiting N; Drachman JG
J Clin Oncol; 2009 Sep; 27(26):4371-7. PubMed ID: 19636010
[TBL] [Abstract][Full Text] [Related]
35. Dosimetry-based therapy in metastatic breast cancer patients using 90Y monoclonal antibody 170H.82 with autologous stem cell support and cyclosporin A.
Richman CM; DeNardo SJ; O'Donnell RT; Goldstein DS; Shen S; Kukis DL; Kroger LA; Yuan A; Boniface GR; Griffith IJ; DeNardo GL
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3243s-3248s. PubMed ID: 10541370
[TBL] [Abstract][Full Text] [Related]
36. Radioimmunotherapy for breast cancer using indium-111/yttrium-90 BrE-3: results of a phase I clinical trial.
DeNardo SJ; Kramer EL; O'Donnell RT; Richman CM; Salako QA; Shen S; Noz M; Glenn SD; Ceriani RL; DeNardo GL
J Nucl Med; 1997 Aug; 38(8):1180-5. PubMed ID: 9255145
[TBL] [Abstract][Full Text] [Related]
37. A pilot study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated, diffuse large B-cell lymphoma.
Micallef IN; Kahl BS; Maurer MJ; Dogan A; Ansell SM; Colgan JP; Geyer S; Inwards DJ; White WL; Habermann TM
Cancer; 2006 Dec; 107(12):2826-32. PubMed ID: 17099879
[TBL] [Abstract][Full Text] [Related]
38. Radioimmunotherapy of refractory or relapsed Hodgkin's lymphoma with 90Y-labelled antiferritin antibody.
Decaudin D; Levy R; Lokiec F; Morschhauser F; Djeridane M; Kadouche J; Pecking A
Anticancer Drugs; 2007 Jul; 18(6):725-31. PubMed ID: 17762404
[TBL] [Abstract][Full Text] [Related]
39. Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer.
Knox SJ; Goris ML; Tempero M; Weiden PL; Gentner L; Breitz H; Adams GP; Axworthy D; Gaffigan S; Bryan K; Fisher DR; Colcher D; Horak ID; Weiner LM
Clin Cancer Res; 2000 Feb; 6(2):406-14. PubMed ID: 10690517
[TBL] [Abstract][Full Text] [Related]
40. Preclinical and clinical evaluation of epratuzumab (anti-CD22 IgG) in B-cell malignancies.
Leonard JP; Goldenberg DM
Oncogene; 2007 May; 26(25):3704-13. PubMed ID: 17530024
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
